Add a company based in Baltimore’s University of Maryland BioPark to this week’s Money Moves.
Gliknik, a company developing treatments for people with cancer and autoimmune diseases, announced completion of its Series C round.
The company raised $11.5 million in a round led by First in Ventures (FIV). Also participating were SAISO Partners, and affiliates of RDA Ventures and Garden Street Holdings.
“We believe that Gliknik has created several potential best-in-class mid-stage assets,” said Scott Roth, managing partner of FIV, in a statement. “This capital will help unlock the potential of these compounds and uniquely positions Gliknik to make a difference for patients with cancer or autoimmune disorders.”
The funding will help the company progress on trial work for three of its treatments in development. They include:
- biropepimut-S, which is in a clinical trial phase. This is designed for high-risk squamous cell cancer of the oral cavity.
- GL-2045, which treats autoimmune diseases. It is under development by Pfizer, to which Gliknik licensed technology.
- GL-0719, which is “designed to control diseases while leaving critical host systems intact,” the company said in a statement. It is slated for a clinical trial in 2021.
The company also has additional treatments in its pipeline that the funding will help develop.
In all, 14-year-old Gliknik has now raised $81 million in funding. The company is among a group of businesses developing new kinds of therapeutics and treatments for diseases that are clustered around the city’s health and research institutions.
Knowledge is power!
Subscribe for free today and stay up to date with news and tips you need to grow your career and connect with our vibrant tech community.